Held by 3 specialist biotech funds
High Convergence# Signal Note: RTW Investments Initiates $6M Position in Inventiva RTW's entry into IVEVF suggests conviction in Inventiva's pipeline, likely centered on **lanifibranor (LAN)** for **non-alcoholic steatohepatitis (NASH)**, which is progressing through late-stage development with potential near-term catalysts.
AI analyst context — unlock full analysis
# Signal Note: BVF Partners Initiates Inventiva Position Mark Lampert's concentrated biotech value strategy entering IVEVF at $3.2M suggests conviction in Inventiva's pipeline economics, likely centered on odiparcil (Thver-004) for mucopolysaccharidosis type 6, which reported Phase 2b data in 2023 and is advancing toward pivotal studies. The entry timing aligns with near-term catalysts including regulatory interactions and potential partnership discussions, though the modest position size ($3.2M) indicates either early conviction-building or valuation-constrained entry into a small-cap name (~€20-25M market cap).
+ 1more — see how much conviction went in
See the Full Story